We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Postmarket Study Guidance Needs Safety Signals
Postmarket Study Guidance Needs Safety Signals
November 13, 2009
Stakeholders are telling the FDA that a July draft guidance on postmarketing studies should have described the safety signals the agency uses to determine that a postmarket clinical trial or study will be required.